Redeye updates its estimates and valuation following Lagercrantz’s Q1 2025/2026 report. Margins matched our projections, while sales and EBITA fell slightly short of what we pencilled in. Still, we judge the company demonstrated its resilience despite a challenging business environment. We believe M&A momentum will remain solid in coming quarters.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/